FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

VI I I I C /		<b>NOTIATIOE</b>	001014
Washington.	D.C. 2054	19	

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated averag	e burden								

0.5

hours per response:

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	f Reporting Person*												(C	heck all app	olicable) ctor		10% Ov	vner
(Last) (First) (Middle) C/O FULGENT GENETICS, INC. 4399 SANTA ANITA AVENUE			3. Date of Earliest Transaction (Month/Day/Year) 12/01/2024								below) below)  CFO and Treasurer							
				4. If A	Amend	ment,	Date o	f Origina	al File	d (Month/Da	ıy/Yea	ear)	Lir	ne) Form	i filed by On	e Repo	orting Perso	on
	Table	I - No	n-Deriva	tive S	Secu	rities	Acq	uired	, Dis	posed of	, or	r Ben	eficia	ally Own	ed			
Date				Execution Date,							Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code	v	Amount	(A (I	A) or D)	Price	Transa	ction(s)			(1110111. 4)
Common Stock 12/01/2				/2024		F		1,553(1)		D	\$18	8.3 204,521			D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
Title of conversion or Exercise price of Derivative Security  3. Transaction Date (Month/Day/Year)  (Month/Day/Year)  3. A. Deemed Execution Date, if any (Month/Day/Year)		Code ( 8)	Instr.	of Deriv Secu Acqu (A) or Dispo of (D) (Instr	rative rities ired r osed ) : 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Expiration		Amour or Numbe		f g nstr. ount	8. Price of Derivative Security (Instr. 5)	derivative Securities Beneficiall Owned Following Reported	y	Ownership Form: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
	(F LGENT GE NTA ANI  VTE C.  (S Security (Ins  Stock	(First) (I LGENT GENETICS, INC. NTA ANITA AVENUE  NTE CA 9  (State) (Z  Table  Security (Instr. 3)  Stock  Tal  2. Conversion or Exercise Price of Derivative (Month/Day/Year)	(First) (Middle)  LGENT GENETICS, INC.  NTA ANITA AVENUE  VTE CA 91731  (State) (Zip)  Table I - No  Security (Instr. 3)  Stock  Table II -  2. Conversion or Exercise Price of Derivative (Month/Day/Year) (Month.)	(First) (Middle)  LGENT GENETICS, INC.  NTA ANITA AVENUE  VTE CA 91731  (State) (Zip)  Table I - Non-Deriva  Security (Instr. 3)  2. Transaction Date (Month/Da)  Stock  Table II - Derivati (e.g., pu  Conversion or Exercise Price of Derivative (Month/Day/Year)  [Conversion or Exercise Price of Derivative]	Full  (First) (Middle)  GENT GENETICS, INC.  NTA ANITA AVENUE  Table I - Non-Derivative Security (Instr. 3)  Stock  Table II - Derivative Security (e.g., puts, cathering of Exercise Price of Derivative Security  (Month/Day/Year)  3. Da 12/0  4. If A  2. Transaction Date (Month/Day/Year)  Stock  Table II - Derivative Security (if any (Month/Day/Year))  3. Date (e.g., puts, cathering of Execution Date, if any (Month/Day/Year)  4. Transaction Date (Month/Day/Year)  Security  1. Transaction Date (Month/Day/Year)  2. Transaction Date (e.g., puts, cathering of Execution Date, if any (Month/Day/Year)  3. Date (Month/Day/Year)	Fulgent  (First) (Middle)  GENT GENETICS, INC.  NTA ANITA AVENUE  Table I - Non-Derivative Security (Instr. 3)  Stock  Table II - Derivative Security (Month/Day/Year)  Table II - Derivative Security (e.g., puts, calls, v. (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  Stock  Table II - Derivative Security (e.g., puts, calls, v. (Month/Day/Year)  A. If Amend  2. Transaction Date (e.g., puts, calls, v. (Month/Day/Year)  3. Date of Elevative Security  4. If Amend  4. Transaction Code (Instr. 8)	Fulgent Gen  Fulgent Gen  Gent Genetics, Inc.  NTA ANITA AVENUE  Table I - Non-Derivative Securities  Security (Instr. 3)  Stock  Table II - Derivative Securities A  (e.g., puts, calls, warra  2. Transaction Date (Month/Day/Year)  Table II - Derivative Securities A  (e.g., puts, calls, warra  3. Date of Earliest 12/01/2024  4. If Amendment,  Year)  And Date (Month/Day/Year)  Stock  Table II - Derivative Securities A  (e.g., puts, calls, warra  And Date (Month/Day/Year)  Security  And Demed Execution Date if any (Month/Day/Year)  Privative Securities A  (e.g., puts, calls, warra  And Date Ocode (Instr. 8)  Security (Instr. 3)  And Demed Execution Date if any (Month/Day/Year)  Security  Security  And Date Ocode (Instr. 8)	Fulgent Genetics  Fulgent Genetics  Security (Instr. 3)  Table I - Non-Derivative Securities Acque (Month/Day/Year)  Fulgent Genetics  3. Date of Earliest Trans. 12/01/2024  4. If Amendment, Date of Execution Date (Month/Day/Year)  Table II - Non-Derivative Securities Acque (Month/Day/Year)  Stock  Table II - Derivative Securities Acque (e.g., puts, calls, warrants, and concept of Date (Month/Day/Year)  Table II - Derivative Securities Acque (month/Day/Year)  Stock  Table II - Derivative Securities Acque (month/Day/Year)  A. Deemed Execution Date (month/Day/Year)  Table II - Derivative Securities Acque (month/Day/Year)  Stock  Table II - Derivative Securities Acque (month/Day/Year)  A. Deemed Execution Date (month/Day/Year)  Stock  Table II - Derivative Securities Acque (month/Day/Year)  Stock  Table II - Derivative Securities Acque (month/Day/Year)  A. Deemed Execution Date (month/Day/Year)  Stock  Table II - Derivative Securities Acque (month/Day/Year)	Fulgent Genetics, Inc.    Fulgent Genetics   Inc.	Fulgent Genetics, Inc. [FL    FL   FL   FL	Fulgent Genetics, Inc. [FLGT]  GENT GENETICS, INC.  NTA ANITA AVENUE  Table I - Non-Derivative Securities Acquired, Disposed of (Security (Instr. 3)    2. Transaction Date (Month/Day/Year)   (Month/Day/Y	Fulgent Genetics, Inc. [FLGT]    Security (Instr. 3)   Security (Instr. 3)   Security (Instr. 3)   Table II - Derivative Securities Acquired, Disposed of, Of (Month/Day/Year)   Security (Month/Day/Year)   Security (State)   Security (Month/Day/Year)   Se	Fulgent Genetics, Inc. [FLGT]  (First) (Middle) GENT GENETICS, INC. NTA ANITA AVENUE  Table I - Non-Derivative Securities Acquired, Disposed of, or Benefic (Month/Day/Year)  Security (Instr. 3)  Table II - Derivative Securities Acquired, Disposed Of (D) (Instr. flar)  (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed Of (D) (Instr. flar)  (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed Of (D) (Instr. flar)  (Code   V   Amount   (A) or (D)	Fulgent Genetics, Inc.   FLGT	Fulgent Genetics, Inc. [FLGT]  (Check all app Direct Derivative Securities Acquired, Disposed of, or Beneficially Own Security (Instr. 3)  Table I - Non-Derivative Securities Acquired, Disposed of (D) (Instr. 3, 4 and 5)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Own Security (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3, 4 and 5)  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3, 4 and 5)  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3, 4 and 5)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owne (e.g., puts, calls, warrants, options, convertible securities)  2. Transaction Date (Bacculion Date, If any (Month/Day/Year) (Mon	Fulgent Genetics, Inc. [FLGT]    Fulgent Genetics, Inc.   FLGT]   Genetics   Genetics	Fulgent Genetics, Inc. [FLGT]    Check all applicable)   Director Officer (give title below)	Fulgent Genetics, Inc. [FLGT]    FLGT

## **Explanation of Responses:**

1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022.

/s/ Paul Kim

12/04/2024

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.